Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.
作者信息
Subbiah Vivek, Hong David S, Meric-Bernstam Funda
机构信息
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
出版信息
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1419-20. doi: 10.1073/pnas.1522052113. Epub 2016 Feb 25.
Abstract
摘要
相似文献
1
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.色瑞替尼在ROS1重排非小细胞肺癌中的临床活性：从 bench 到床边报告
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1419-20. doi: 10.1073/pnas.1522052113. Epub 2016 Feb 25.
2
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.ROS1酪氨酸激酶抑制剂选择性和耐药性概况的结构洞察
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.
3
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.ROS1蛋白酪氨酸激酶抑制剂在治疗ROS1融合蛋白驱动的非小细胞肺癌中的应用
Pharmacol Res. 2017 Jul;121:202-212. doi: 10.1016/j.phrs.2017.04.022. Epub 2017 Apr 30.
4
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.ROS1 重排非小细胞肺癌获得克唑替尼耐药相关的分子变化。
Clin Cancer Res. 2015 May 15;21(10):2379-87. doi: 10.1158/1078-0432.CCR-14-1350. Epub 2015 Feb 16.
5
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.间变性淋巴瘤激酶（ALK）和原癌基因酪氨酸蛋白激酶ROS1作为靶向治疗模式及克服克唑替尼耐药性的临床意义
Oncotarget. 2016 Mar 15;7(11):12289-304. doi: 10.18632/oncotarget.6935.
6
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.一种激活型KIT突变诱导ROS1阳性肺癌对克唑替尼耐药。
J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.
7
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.非小细胞肺癌中的癌基因成瘾：聚焦 ROS1 抑制。
Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12.
8
Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.将ALK和ROS1抑制剂与其他药物联合用于治疗非小细胞肺癌。
Clin Adv Hematol Oncol. 2015 May;13(5):282-4.
9
Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.发现新型2,4-二芳基氨基嘧啶类似物作为ALK和ROS1双重抑制剂，以克服包括G1202R在内的克唑替尼耐药突变体。
Eur J Med Chem. 2018 Jan 1;143:123-136. doi: 10.1016/j.ejmech.2017.11.008. Epub 2017 Nov 6.
10
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.卡博替尼可克服ROS1融合阳性癌症中的克唑替尼耐药性。
Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.
引用本文的文献
1
Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations.发现具有针对次级耐药突变强效活性的 ROS1 融合蛋白口服降解剂。
J Med Chem. 2024 Oct 24;67(20):18098-18123. doi: 10.1021/acs.jmedchem.4c01205. Epub 2024 Oct 3.
2
Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.口服生物可利用的2,4-二芳基氨基嘧啶类似物（DAAP类似物）作为间变性淋巴瘤激酶抑制剂的最新研究进展：发现与临床进展
RSC Adv. 2018 May 4;8(30):16470-16493. doi: 10.1039/c8ra01934g. eCollection 2018 May 3.
3
Response to Crizotinib in Fusion-Positive Intrahepatic Cholangiocarcinoma.克唑替尼对融合阳性肝内胆管癌的疗效
JCO Precis Oncol. 2020 Nov;4:825-828. doi: 10.1200/PO.20.00116.
4
Response to Entrectinib in Differentiated Thyroid Cancer With a Fusion.恩曲替尼对伴有融合的分化型甲状腺癌的反应
JCO Precis Oncol. 2017 Dec 8;1. doi: 10.1200/PO.17.00105. eCollection 2017.
5
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant Rearranged Non-Small-Cell Lung Cancer.布加替尼在克唑替尼和色瑞替尼耐药的重排非小细胞肺癌中的活性。
JCO Precis Oncol. 2019;3. doi: 10.1200/po.18.00267. Epub 2019 Feb 15.
6
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.ROS1 重排非小细胞肺癌的治疗靶点：克唑替尼和新一代酪氨酸激酶抑制剂。
Drugs. 2019 Aug;79(12):1277-1286. doi: 10.1007/s40265-019-01164-3.
7
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.非小细胞肺癌治疗选择的预测生物标志物最新进展
J Clin Med. 2018 Jun 15;7(6):153. doi: 10.3390/jcm7060153.
8
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?肺癌中新兴的耐药途径：ROS-1给了我们什么启示？
Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S9-S12. doi: 10.21037/tlcr.2017.11.13.
9
Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.高加索非小细胞肺癌患者的致癌驱动基因突变、治疗及表皮生长因子受体酪氨酸激酶抑制剂耐药性：临床实践中的生存情况
Oncotarget. 2017 Sep 13;8(44):77897-77914. doi: 10.18632/oncotarget.20857. eCollection 2017 Sep 29.
10
Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs.在晚期非小细胞肺癌初始检查中确定优先检测的分子标志物：需求与期望。
Ann Transl Med. 2017 Sep;5(18):371. doi: 10.21037/atm.2017.08.29.
本文引用的文献
1
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.ROS1酪氨酸激酶抑制剂选择性和耐药性概况的结构洞察
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.
2
The Signature Program: Bringing the Protocol to the Patient.标志性项目：将方案应用于患者。
Clin Pharmacol Ther. 2015 Aug;98(2):124-6. doi: 10.1002/cpt.126. Epub 2015 May 11.
3
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.
4
Ceritinib in ALK-rearranged non-small-cell lung cancer.色瑞替尼治疗ALK重排的非小细胞肺癌
N Engl J Med. 2014 Jun 26;370(26):2537. doi: 10.1056/NEJMc1404894.
5
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
Zotero 插件